20 citations
,
May 2015 in “Regenerative Medicine” This commentary explores the marketing of unproven and unlicensed adipose-derived stem cell treatments in US clinics, highlighting concerns about patient safety and regulatory challenges.
May 2019 in “Cytotherapy” This study explored how Australian patients and their carers perceived autologous stem cell interventions, highlighting factors like illness experience and unrealistic expectations that influenced their decision-making in an unregulated market.
39 citations
,
August 2016 in “Journal of Dermatological Treatment” This study observed that autologous bone marrow derived mononuclear cells and follicular stem cells were both safe and effective for improving resistant alopecia areata and androgenetic alopecia, with no serious adverse events.
3 citations
,
May 2019 in “Cytotherapy” In this study, only a subset of proposed biomarkers universally responded to priming in mesenchymal stromal cells, suggesting limited utility for standardized potency assays across different MSC types and conditions.
1 citations
,
May 2019 in “Cytotherapy” This study reviewed changes in marketing practices of Australian clinics after a regulatory ban on direct-to-consumer advertising of stem cell products, finding improvements yet also limitations in addressing misleading claims and consumer safety.